Jun 2026 (Q2 FY26) — Aug 5, 2026
Envista Holdings Q2 FY26 — Strong Core Growth and Raised Full-Year Guidance
Read the full callEnvista Holdings (NVST) earnings
- Jul 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Envista Holdings earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 731 | +7.1% YoY | Quarterly, as filed | Quarter to Jul 2026 | Revenue from operations as filed. |
| Operating margin | 11.0 | +4.2 pts YoY | Operating profit / revenue | Quarter to Jul 2026 | For the quarter; a change is in percentage points. |
| Net profit | 53.7 | +103.4% YoY | Quarterly, as filed | Quarter to Jul 2026 | Profit after tax as filed. |
Price
$23.5 +2.98% · +$0.68
Performance +20.8% 1Y
1Y: $19.45 on 14 Oct 2025 → $23.5. High $30.26 (11 Feb 2026), low $18.95 (19 Nov 2025).
- Previous close
- $22.82
- 52-week range
- $18.95 – $30.26
- One year
- +19.84%
Overview
- Symbol
- NVST
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 6, 2026
Envista Q1 FY26 — Strong Start to Year with Broad-Based Growth and Reaffirmed Guidance
Read the full callEvery analysed call
Envista Holdings earnings calls (NVST)
Financials
What the filings say
Net profit, year on year: +103% (quarter to jul 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 601 | 653 | 617 | 682 | 670 | 751 | 706 | 731 |
| Operating profit | 21 | 46 | 39 | 46 | 58 | 73 | 63 | 80 |
| Operating margin | 3.5% | 7.1% | 6.3% | 6.8% | 8.6% | 9.8% | 8.9% | 11.0% |
| Profit before tax | 10 | 37 | 29 | 41 | 50 | 58 | 52 | 74 |
| Tax rate | 14.6% | 96.7% | 37.9% | 35.1% | 160.7% | 42.9% | 25.9% | 27.8% |
| Net profit | 8 | 1 | 18 | 26 | -30 | 33 | 39 | 54 |
| EPS ($ per share) | 0.05 | — | 0.10 | 0.16 | -0.18 | — | 0.24 | 0.33 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Reserves | 0 | 93 | 126 | 467 | 731 | 631 | -487 | -440 |
| Total liabilities | 1,015 | 2,616 | 3,155 | 2,516 | 2,380 | 2,431 | 2,416 | 2,573 |
| Fixed assets | 262 | 290 | 275 | 264 | 294 | 310 | 277 | 297 |
| Total assets | 5,842 | 6,158 | 6,876 | 6,574 | 6,587 | 6,605 | 5,351 | 5,679 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 400 | 398 | 284 | 362 | 183 | 276 | 337 | 276 |
| Cash from investing | -75 | -78 | -69 | 263 | -657 | -62 | -55 | -51 |
| Cash from financing | -325 | -108 | 493 | -466 | 13 | 119 | -104 | -171 |
| Net cash flow | 0 | 211 | 678 | 185 | -467 | 333 | 129 | 143 |
| Capital expenditure | -72 | -78 | -48 | -55 | -76 | -58 | -34 | -45 |
| Free cash flow | 328 | 320 | 236 | 307 | 107 | 218 | 303 | 230 |
Insider filings
35 filings between Nov 1, 2025 and Aug 25, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$510.3K
3 sales by 1 insider
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 16
- Award — granted as compensation
- 2
- Option exercise — converted options into shares
- 14
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Reis Mischa | — | $510.3K | Aug 20, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 25, 2026 | Acurio Veronica President, Orthodontics | Tax withheld | 7,710 | $211.8K |
| Aug 25, 2026 | Nilsson Stefan President, Nobel Biocare | Tax withheld | 804 | $22.1K |
| Aug 25, 2026 | Befidi Robert President, Diagnostics | Tax withheld | 5,147 | $141.4K |
| Aug 25, 2026 | Hammes Eric D. Chief Financial Officer | Tax withheld | 10,885 | $299.0K |
| Aug 20, 2026 | Reis Mischa SVP, Strategy & Bus. Dev. | Sale 10b5-1 plan | 8,000 | $220.0K |
| Aug 18, 2026 | Keel Paul A Chief Executive Officer | Award | 179,730 | $0 |
| May 25, 2026 | Keel Paul A Chief Executive Officer | Tax withheld | 12,811 | $300.2K |
| May 19, 2026 | GALLAHUE KIERAN Director | Award | 9,330 | $0 |
| May 19, 2026 | Carruthers Wendy Director | Award | 9,330 | $0 |
| May 19, 2026 | Pierce James Andrew Director | Award | 9,330 | $0 |
| May 19, 2026 | TSINGOS CHRISTINE A Director | Award | 9,330 | $0 |
| May 19, 2026 | Raskas Daniel Director | Award | 9,330 | $0 |
| May 19, 2026 | Jain Vivek Director | Award | 9,330 | $0 |
| May 19, 2026 | Huennekens R Scott Director | Award | 12,585 | $0 |
| Feb 25, 2026 | Nilsson Stefan President, Nobel Biocare | Award | 7,605 | $0 |
| Feb 25, 2026 | Acurio Veronica President, Orthodontics | Award | 7,605 | $0 |
| Feb 25, 2026 | Acurio Veronica President, Orthodontics | Tax withheld | 1,412 | $41.8K |
| Feb 25, 2026 | Keel Paul A Chief Executive Officer | Tax withheld | 11,840 | $350.3K |
| Feb 25, 2026 | Hammes Eric D. Chief Financial Officer | Award | 16,055 | $0 |
| Feb 25, 2026 | Hammes Eric D. Chief Financial Officer | Tax withheld | 2,045 | $60.5K |
| Feb 25, 2026 | Keel Paul A Chief Executive Officer | Award | 48,670 | $0 |
| Feb 25, 2026 | Nance Mark E General Counsel | Tax withheld | 3,368 | $99.7K |
| Feb 25, 2026 | Nance Mark E General Counsel | Award | 12,675 | $0 |
| Feb 25, 2026 | Reis Mischa SVP, Strategy & Bus. Dev. | Tax withheld | 2,976 | $88.1K |
| Feb 25, 2026 | Reis Mischa SVP, Strategy & Bus. Dev. | Award | 5,915 | $0 |
| Feb 25, 2026 | Kaabi Faez C Chief Accounting Officer | Tax withheld | 4,964 | $146.9K |
| Feb 25, 2026 | Kaabi Faez C Chief Accounting Officer | Award | 13,520 | $0 |
| Feb 25, 2026 | Befidi Robert President, Diagnostics | Tax withheld | 2,177 | $64.4K |
| Feb 25, 2026 | Befidi Robert President, Diagnostics | Award | 7,605 | $0 |
| Feb 25, 2026 | Nilsson Stefan President, Nobel Biocare | Tax withheld | 182 | $5.4K |
| Feb 10, 2026 | Reis Mischa SVP, Strategy & Bus. Dev. | Sale 10b5-1 plan | 5,634 | $169.0K |
| Feb 10, 2026 | Reis Mischa SVP, Strategy & Bus. Dev. | Option exercise 10b5-1 plan | 5,634 | $90.0K |
| Feb 10, 2026 | Reis Mischa SVP, Strategy & Bus. Dev. | Sale 10b5-1 plan | 4,041 | $121.2K |
| Feb 10, 2026 | Reis Mischa SVP, Strategy & Bus. Dev. | Option exercise 10b5-1 plan | 4,041 | $76.9K |
| Nov 1, 2025 | Keel Paul A Chief Executive Officer | Tax withheld | 54,097 | $1.10M |
| Aug 25, 2025 | Hammes Eric D. Chief Financial Officer | Tax withheld | 7,654 | $161.7K |
| Aug 25, 2025 | Reis Mischa SVP, Strategy & Bus. Dev. | Sale 10b5-1 plan | 15,000 | $324.0K |
| Aug 25, 2025 | Befidi Robert President, Diagnostics | Tax withheld | 3,454 | $72.9K |
| Aug 25, 2025 | Nilsson Stefan President, Nobel Biocare | Tax withheld | 804 | $17.0K |
| Aug 25, 2025 | Acurio Veronica President, Orthodontics | Tax withheld | 5,422 | $114.5K |
| Jul 14, 2025 | Pierce James Andrew Director | Award | 9,155 | $0 |
| Jun 10, 2025 | Raskas Daniel Director | Award | 10,450 | $0 |
| Jun 10, 2025 | Huennekens R Scott Director | Award | 14,370 | $0 |
| Jun 10, 2025 | Hulit Barbara B. Director | Award | 10,450 | $0 |
| Jun 10, 2025 | TSINGOS CHRISTINE A Director | Award | 10,450 | $0 |
| Jun 10, 2025 | Carruthers Wendy Director | Award | 10,450 | $0 |
| Jun 10, 2025 | Jain Vivek Director | Award | 10,450 | $0 |
| Jun 10, 2025 | GALLAHUE KIERAN Director | Award | 10,450 | $0 |
| May 25, 2025 | Keel Paul A Chief Executive Officer | Tax withheld | 12,787 | $213.8K |
| Feb 26, 2025 | Reis Mischa SVP, Strategy & Bus. Dev. | Award | 8,475 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Envista Holdings Corp
Free account. Everything above stays public.
Write why you follow Envista Holdings Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading